From the Journals

Quicker fertility rebound in young women with breast cancer


 

Higher pregnancy rates

Almost 18% of women in the experimental arm reported trying to conceive, and 9.6% of them did so. About 10% of women in the cyclophosphamide arm tried to conceive, and 2.7% did so (P = .03).

The median interval between randomization and pregnancy was 42 months.

For all of the women who became pregnant, endocrine therapy was interrupted. “Women who temporarily interrupt endocrine therapy due to pregnancy should be reminded to resume endocrine therapy following attempted or successful pregnancy,” the investigators wrote.

The patients were taking tamoxifen at least 5 years after receiving chemotherapy, most often as monotherapy. About 5% of the patients underwent up-front ovarian suppression with an aromatase inhibitor, which is a current standard option.

The study was supported by the National Natural Science Foundation of China and other organizations. The investigators and Dr. Partridge disclosed no relevant financial relationships. Dr. Lambertini has consulted for and/or has received speakers fees from Roche, AstraZeneca, Lilly, Novartis, and other companies.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Breast cancer mortality in under 40s resparks screening debate
MDedge Internal Medicine
Anthracycline-free neoadjuvant regimen safe, effective for TNBC
MDedge Internal Medicine
SNP chips deemed ‘extremely unreliable’ for identifying rare variants
MDedge Internal Medicine
Most breast cancer screening centers not following guidelines
MDedge Internal Medicine
Could tamoxifen dose be slashed down to 2.5 mg? 
MDedge Internal Medicine
Huge, struggling breast cancer screening trial gets lifeline
MDedge Internal Medicine
Risk-based mammography proposed for times of reduced capacity
MDedge Internal Medicine
Treating metastatic TNBC: Where are we now?
MDedge Internal Medicine
Cancer screening stopped by pandemic: Repercussions to come?
MDedge Internal Medicine
Rankings of most common cancers to shift over next 20 years
MDedge Internal Medicine